Double Bond Pharmaceutical International ABNGM: DBP.B

DBP.B: Q1 2026 delivered narrowed losses and major clinical validation for Temodex

· Issued by Double Bond Pharmaceutical International AB

Q1 2026 saw improved financials with narrowed losses and a significant scientific milestone as Temodex demonstrated a 5.6-month survival benefit. Strategic focus is on licensing, portfolio control, and leveraging new clinical data for commercial growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Double Bond Pharmaceutical International AB on 6ix

Earlier from Double Bond Pharmaceutical International

All Double Bond Pharmaceutical International news releases